Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Saturday morning. The brokerage issued a sell rating on the stock.

Oragenics Stock Performance

OGEN stock opened at $0.51 on Friday. Oragenics has a one year low of $0.47 and a one year high of $7.74. The firm’s fifty day moving average is $1.09 and its 200 day moving average is $1.41. The firm has a market cap of $2.29 million, a PE ratio of -0.06 and a beta of 0.50.

Oragenics (NYSE:OGEN) last posted its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Trading of Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC acquired a new stake in Oragenics, Inc. (NYSE:OGEN) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics as of its most recent filing with the SEC. Institutional investors and hedge funds own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.